


PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop DD, P.O. Box 1450, Alexandria, VA, 22313-1450, on January 6, 2004.


Ginger M. Graff Date 1/6/04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/645,977
Filing Date: August 22, 2003
Applicant(s): Jeffrey S. Kiel, et al.
Title: **PHENYLEPHRINE TANNATE, PYRILAMINE TANNATE, AND
DEXTROMETHORPHAN TANNATE SALTS IN
PHARMACEUTICAL COMPOSITIONS**
Examiner: Unknown
Group Art Unit: 1614
Conf. No: 8380
Atty Docket No: PEDI-16

Cincinnati, Ohio

January 6, 2004

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
FILED PURSUANT TO 37 CFR §§ 1.56 AND 1.97-1.98

Sir:

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56, and the means of complying with that duty according to 37 C.F.R. §§1.97 and 1.98, the Applicants call the references listed on the attached form PTO-1449 to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. An Information Disclosure Statement with U.S.

patents is being electronically filed on even date herewith. The Applicants have enclosed a copy of all other cited references.

The Applicants respectfully believe that the cited references, either individually or in combination, do not disclose or render obvious the subject matter claimed in the present application. Nonetheless, the Applicants request that the Examiner review the references and make an independent determination of their relevance.

The Applicants do not believe that any fees are due in connection with this submission. However, if such fees are necessary, the Commissioner is authorized to charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By: 
David E. Jeffries, Reg. No. 46,800

Wood, Herron & Evans, L.L.P.
2700 Carew Tower
Cincinnati, OH 45202
(513) 241-2324 (voice)
(513) 421-7269 (facsimile)

JAN 08 2004

Sheet 1 (A) of 1

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PEDI/16SERIAL NO.
10/645,977INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Jeffrey S. Kiel, et al.

(Use several sheets if necessary)

FILING DATE
August 22, 2003GROUP
1614

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	R.I. Goldberg et al., <u>Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders</u> , Clinical Medicine, (Sept. 1965) 1475-1478.
A.S	J.M. Weiler et al., <u>Randomized double-blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan® in the treatment of allergic rhinitis using an acute model</u> , Annals of Allergy, Vol. 64, No. 1, (Jan. 1990), 63-67.
A.T	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)